|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-6-10
|
|
pubmed:abstractText |
The safety and good tolerability of sublingual immunotherapy (SLIT) has already been proved in allergic patients, but only one study has investigated the occurrence of immediate adverse reactions in allergic patients after a 2-hour ultra-rush regimen of SLIT performed with a chemically modified extract (sublingual monomeric allergoid, Lais, Lofarma S.p.A., Milan). The objective of the present study was to evaluate the occurrence of immediate adverse reactions in allergic patients after a very fast (20 minutes) ultra-rush regimen of sublingual allergoid SLIT.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0301-0546
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
142-4
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15946626-Administration, Sublingual,
pubmed-meshheading:15946626-Adolescent,
pubmed-meshheading:15946626-Adult,
pubmed-meshheading:15946626-Allergens,
pubmed-meshheading:15946626-Asthma,
pubmed-meshheading:15946626-Child,
pubmed-meshheading:15946626-Desensitization, Immunologic,
pubmed-meshheading:15946626-Dose-Response Relationship, Immunologic,
pubmed-meshheading:15946626-Drug Administration Schedule,
pubmed-meshheading:15946626-Female,
pubmed-meshheading:15946626-Heartburn,
pubmed-meshheading:15946626-Humans,
pubmed-meshheading:15946626-Male,
pubmed-meshheading:15946626-Middle Aged,
pubmed-meshheading:15946626-Rhinitis, Allergic, Perennial,
pubmed-meshheading:15946626-Rhinitis, Allergic, Seasonal,
pubmed-meshheading:15946626-Solubility,
pubmed-meshheading:15946626-Tablets
|
|
pubmed:articleTitle |
Safety and tolerability of ultra-Rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
|
|
pubmed:affiliation |
Respiratory Center Disease-USL 5, Messina, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
